First CRISPR Eye Fix Brings Hope

For most of human history, inherited blindness was simply fate—a genetic sentence with no appeal. In March 2020, a patient at Oregon Health & Science University became the first person to have their DNA edited inside their body, receiving CRISPR gene therapy injected directly into the back of their eye. Four years later, we finally know if it worked.

The Disease That Gene Therapy Couldn't Reach

Leber Congenital Amaurosis Type 10 sounds obscure, but it represents something bigger: a class of genetic diseases that our previous tools simply couldn't fix. Children born with LCA10 lose their vision in infancy or early childhood, the result of a mutation in the CEP290 gene that prevents light-sensing cells in the retina from functioning properly.

Traditional gene therapy seemed like the obvious solution. Take a working copy of the gene, package it into a virus, inject it into the eye, and let the virus deliver the genetic fix. This approach has already restored vision in other forms of inherited blindness. But CEP290 is too large—7,440 base pairs—to fit inside the adeno-associated viruses that serve as our standard delivery vehicles. They max out at around 4,700 base pairs.

CRISPR offered a different approach: instead of replacing the entire gene, just edit out the mutation. The most common LCA10 mutation sits in a non-coding region of the gene, creating a defect that disrupts normal protein production. Remove that section, and the gene can function again.

Editing Genes in the Dark

The BRILLIANCE trial enrolled 14 patients—12 adults and 2 children—who received a single injection of EDIT-101 into one eye. The treatment delivers the CRISPR molecular machinery in a viral package, where it cuts out the problematic genetic sequence and allows the cells to repair themselves.

The stakes were higher than just whether vision would improve. This was the first time CRISPR had been used to edit genes inside a living human body, rather than extracting cells, editing them in a lab, and returning them. The immune system could have attacked the foreign Cas9 protein. The editing could have gone wrong, cutting DNA in unintended places. The procedure itself—injecting under the retina—carried surgical risks.

None of those disasters materialized. Through 15 months of follow-up, researchers found no serious treatment-related complications, no immune responses against the editing machinery, and no signs of off-target editing effects. Dr. Eric Pierce, who led the trial at Mass Eye and Ear, noted that establishing safety was itself a major milestone for in-body gene editing.

Measuring Vision in People Who've Never Seen

The efficacy results tell a more complex story. Eleven of the 14 participants—79%—showed improvement in at least one measure of vision. Six showed improvements in multiple measures. Four could read more lines on an eye chart than before. Six showed better cone-mediated vision, which governs daytime and color vision.

Those percentages might sound modest, but the baseline matters. These were people who couldn't read any lines on a standard eye chart. Some couldn't see well enough to know if their coffee maker was on. The improvements that mattered most weren't captured by clinical measures at all—they were things like finally being able to see the food on their plate, or locating a misplaced phone.

The trial tested three dose levels, and the results suggest a dose-response relationship, with higher doses producing better outcomes. But Editas Medicine, the company sponsoring the trial, paused enrollment in November 2022 and is now seeking partners to continue development. The decision reflects the brutal economics of rare disease treatment: LCA10 affects perhaps 2 to 3 in 100,000 newborns, and developing a treatment through FDA approval costs hundreds of millions of dollars.

What Partial Success Means for Gene Editing

The BRILLIANCE results, published in The New England Journal of Medicine in May 2024, don't represent a cure. Most participants still have severe visual impairment. But they demonstrate something more important: proof of concept that in-body CRISPR editing can work safely and produce measurable benefits.

This matters because CEP290 is just one gene. More than 250 genetic mutations can cause inherited blindness. Thousands more cause other diseases. Many involve genes too large for traditional gene therapy or situations where replacing an entire gene isn't feasible. CRISPR's precision—cutting and editing specific sequences—opens possibilities that weren't available before.

The eye is an ideal testing ground for gene therapy. It's relatively isolated from the rest of the body, reducing the risk that editing machinery will spread to unintended tissues. It's small, requiring less therapeutic material. And it's easy to monitor for both benefits and side effects. Success in the eye provides a roadmap for editing genes in other organs, where the challenges are greater but the potential patient populations are larger.

The Patients Who See a Little More

Two children, ages 10 and 14, were among those treated. They represent the first congenitally blind children to receive gene editing therapy, and both showed significant improvements in daytime vision. The decision to include children in the trial reflects a calculation: intervening earlier, before retinal cells have fully degenerated, might produce better results. It also raises the stakes—editing the genome of a child who will live for decades with the consequences demands even greater certainty about long-term safety.

The adults in the trial had lived with blindness for years or decades. Their improvements, while modest by objective measures, represent something they'd never experienced: vision that got better rather than worse. One measure of success is whether participants chose to have their second eye treated when given the option. Most did.